A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Bioavailability, and Food-effects of EA1080 in Healthy Caucasian and Japanese Male Participants

EA Pharma Co., Ltd.184 enrolled

Overview

The primary purpose of the study is to evaluate the safety and tolerability of EA1080 following single and multiple ascending oral doses in healthy Caucasian and Japanese male participants.

The drug being tested in this study is called EA1080. EA1080 is being tested to find a safe and well-tolerated dose in healthy Caucasian and Japanese male participants. The study consists of 2 parts as mentioned below: Part A: This part of the study is fully adaptive and will be performed in three sub-parts as follows: * Single ascending dose (SAD) * Food Effect (FE) and optional bioavailability * Multiple ascending dose (MAD) Part B: This part of study is comprised of four sub-parts to assess Formulation E and Formulation F as follows: * SAD * An additional FE period in SAD cohorts (SAD-FE) * Food Effect and bioavailability (FE/BA) * MAD

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

QUADRUPLE

Enrollment

184

Conditions

Healthy Volunteers

Interventions

EA1080DRUG

EA1080 Formulation A.

EA1080DRUG

EA1080 Formulation B.

EA1080DRUG

EA1080 Formulation C.

EA1080DRUG

Eligibility

Sex: MALEMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Participants must meet all of the following criteria to be eligible for enrolment in this study: 1. Participants in Caucasian cohorts must be healthy males, aged greater than or equal (\>=) 18 to less than or equal to (\<=) 45 years at the date of signing informed consent 2. Participants in Japanese cohorts must be healthy males, aged \>=20 to \<=45 years at the date of signing informed consent 3. Participants must have a body mass index (BMI) between 18.5-25.0 kilogram per square meter (kg/m\^2) inclusive at screening, Day -3, Day -2 or Day -1. Exclusion Criteria: Participants will be excluded from enrolment in this study if they meet any of the following criteria: 1. Positive test for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening 2. Consumption of herbal remedies or dietary supplements containing St. John's Wort 30 days before the first day of dosing 3. Has donated or lost 400 milliliter (mL) blood or more within the last 16 weeks preceding the first day of dosing 4. An inability to follow a standardised diet and meal schedule or inability to fast, as required during the study 5. Prior screen failure (where the cause of the screen failure is not deemed to be temporary), randomisation, participation, or enrolment in this study. Participants who initially failed due to temporary non-medically significant issues are eligible for re-screening once the cause has resolved 6. Participants with veins on either arm that are unsuitable for intravenous puncture or cannulation (example, veins that are difficult to locate, or a tendency to rupture during puncture) 7. Participants with any medical condition which may cause raised intracranial pressure, participants with new or changing headaches, and participants with history of head or spinal trauma 8. An absolute lymphocyte count below 0.9\*10\^9 per liter (/L) at screening or on Day -1 9. Participants in receipt of any vaccination for Corona virus disease (COVID-19) within 14 days prior to the first dose administration. 10. History of COVID-19 polymerase chain reaction (PCR) positivity within 3 months of Day 1, suspected COVID-19 based on clinical presentation within 3 months of Day 1, or presence of clinically relevant long term sequelae of COVID-19. 11. Unwillingness to receive COVID-19 testing per local or site COVID-19 guidance.

Locations (1)

Richmond Pharmacology Ltd

London, United Kingdom

Outcomes

Primary Outcomes

Parts A and B: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

Time frame: Up to approximately 3 year 4 months

Parts A and B: Percentage of Participants With Clinically Significant Change From Baseline in Laboratory Parameter Values

Time frame: Up to approximately 3 year 4 months

Parts A and B: Percentage of Participants With Abnormal, Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG) Findings

Time frame: Up to approximately 3 year 4 months

Parts A and B: Percentage of Participants With Clinically Significant Change From Baseline in Vital Sign Values

Time frame: Up to approximately 3 year 4 months

Secondary Outcomes

Parts A and B: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) of EA1080 and its Metabolite

Time frame: Part A and B, SAD: Pre-dose (Day 1) and up to Day 8; Part A, FE and Part B, SAD and additional FE: Pre-dose (Day 1) and up to Day 15; Part B, FE/BA: Pre-dose (Day 1) and up to Day 22; MAD: Pre-dose (Day 1) and up to Day 28 Part A and up to Day 24 Part B

Parts A and B: T1/2: Terminal Half-life of EA1080 and its Metabolite

Parts A and B: Cmax: Maximum Observed Plasma Concentration of EA1080 and its Metabolite

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

EA1080 Formulation D.

EA1080-matching placeboDRUG

EA1080-matching placebo.

EA1080DRUG

EA1080 Formulation E.

EA1080DRUG

EA1080 Formulation F.

Parts A and B: AUC (0-t): Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration of EA1080 and its Metabolite

Parts A and B: AUC (0-inf): Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time of EA1080 and its Metabolite

Parts A and B: %AUCextrap: Percentage of AUC (0-inf) That is due to Extrapolation From tlast to Infinity of EA1080 and its Metabolite

Time frame: SAD: Pre-dose (Day 1) and up to Day 8; FE and optional BA: Pre-dose (Day 1) and up to Day 15; MAD: Pre-dose (Day 1) and up to Day 28 Part A and up to Day 24 Part B

Parts A and B: CL/F: Apparent Total Body Clearance of EA1080 and its Metabolite

Parts A and B: Vz/F: Apparent Volume of Distribution During the Terminal Phase of EA1080 and its Metabolite

Parts A and B: Ae: Amount of Drug EA1080 Excreted in Urine

Time frame: Part A and B, SAD: Pre-dose (Day 1) and up to Day 5; Part B, SAD and additional FE: Pre-dose (Day 1) and up to Day 5; Part A and B, MAD: Pre-dose (Day 1) and up to Day 25 Part A and Day 21 for Part B

Parts A and B: fe: Percentage of EA1080 and its Metabolite Dose Excreted in Urine

Time frame: Part A and B, SAD: Pre-dose (Day 1) and up to Day 5; Part B, SAD and additional FE: Pre-dose (Day 1) and up to Day 5; MAD: Pre-dose (Day 1) and up to Day 25 Part A and Day 21 for Part B

Parts A and B: CLR: Renal Clearance of EA1080 and its Metabolite

Time frame: Part A and B, SAD: Pre-dose (Day 1) and up to Day 5; Part B, SAD and additional FE: Pre-dose (Day 1) and up to Day 5; MAD: Pre-dose (Day 1) and up to Day 25 Part A and Day 21 for Part B

Parts A and B: AUC (0-τ): Area Under the Plasma Concentration-time Curve From Time Zero to the Final Dosing Interval (τ) of EA1080 and its Metabolite